ES2150447T3 - Formas purificadas de desoxiribonucleasa. - Google Patents

Formas purificadas de desoxiribonucleasa.

Info

Publication number
ES2150447T3
ES2150447T3 ES93914258T ES93914258T ES2150447T3 ES 2150447 T3 ES2150447 T3 ES 2150447T3 ES 93914258 T ES93914258 T ES 93914258T ES 93914258 T ES93914258 T ES 93914258T ES 2150447 T3 ES2150447 T3 ES 2150447T3
Authority
ES
Spain
Prior art keywords
components
deamidated
deoxyribonuclease
purified forms
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93914258T
Other languages
English (en)
Inventor
John Frenz
Steven J Shire
Mary B Sliwkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2150447T3 publication Critical patent/ES2150447T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION PROVEE LA IDENTIFICACION Y CARACTERIZACION DE DOS COMPONENTES DE UNA PREPARACION RECOMBINANTE DE DNASE. ESTOS COMPONENTES SON LAS DNASES HUMANA DESAMIDADA O NO DESAMIDADA PURIFICADA. SE INDICA TAMBIEN LA SEPARACION DE ESTOS COMPONENTES Y LA APLICACION DE LAS ESPECIES NO DESAMIDADAS COMO UN PRODUCTO FARMACEUTICO PER SE, Y EN PARTICULAR EN COMPOSICIONES EN DONDE LAS ESPECIES SON DESCRITAS DENTRO DE UNA VIA PLASTICA, PARA LA APLICACION EN ADMINISTRAR A PACIENTES QUE SUFREN DE AGOTAMIENTO PULMONAR.
ES93914258T 1992-06-08 1993-05-28 Formas purificadas de desoxiribonucleasa. Expired - Lifetime ES2150447T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/895,300 US5279823A (en) 1992-06-08 1992-06-08 Purified forms of DNASE

Publications (1)

Publication Number Publication Date
ES2150447T3 true ES2150447T3 (es) 2000-12-01

Family

ID=25404292

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93914258T Expired - Lifetime ES2150447T3 (es) 1992-06-08 1993-05-28 Formas purificadas de desoxiribonucleasa.

Country Status (30)

Country Link
US (4) US5279823A (es)
EP (2) EP1013284B1 (es)
JP (1) JP3383307B2 (es)
KR (2) KR100302092B1 (es)
AT (2) ATE455557T1 (es)
AU (1) AU682822B2 (es)
BG (1) BG62335B1 (es)
BR (1) BR9306670A (es)
CA (1) CA2137237C (es)
CZ (1) CZ293105B6 (es)
DE (3) DE4392749T1 (es)
DK (1) DK0644932T3 (es)
ES (1) ES2150447T3 (es)
FI (1) FI945549A0 (es)
GB (1) GB2282140B (es)
GE (1) GEP20002300B (es)
GR (1) GR3034718T3 (es)
HU (1) HU219549B (es)
IL (1) IL105724A (es)
MD (1) MD960288A (es)
NO (1) NO318644B1 (es)
NZ (1) NZ253559A (es)
PL (1) PL175873B1 (es)
PT (1) PT644932E (es)
RO (1) RO117188B1 (es)
RU (1) RU2238320C2 (es)
SK (1) SK282957B6 (es)
TJ (1) TJ396B (es)
UA (1) UA46693C2 (es)
WO (1) WO1993025670A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929551T2 (de) * 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
DE69533128T2 (de) * 1994-03-04 2005-06-09 Genentech, Inc., South San Francisco Pharmazeutische akzeptabel dnase zusammensetzung
DE69535787D1 (de) * 1994-03-04 2008-08-28 Genentech Inc Verbesserte dnase flüssige lösungen
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
WO1995030428A1 (en) * 1994-05-05 1995-11-16 Human Genome Sciences, Inc. Human dnase
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
EP0754751B1 (en) * 1994-09-06 2001-09-19 Seiichi Tanuma Novel deoxyribonuclease
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
JP4118334B2 (ja) * 1996-02-05 2008-07-16 ジェネンテック・インコーポレーテッド ヒトｄｎアーゼ
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6489447B1 (en) † 1998-05-06 2002-12-03 Genentech, Inc. Protein purification
AU3500901A (en) * 2000-02-11 2001-08-20 Medic Aid Ltd Drug delivery apparatus
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
DE60135983D1 (de) * 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
MD20010375A (ro) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Malaxor
MD2260C2 (ro) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Malaxor
LT1543038T (lt) 2002-09-11 2017-07-10 Genentech, Inc. Baltymo gryninimas
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US20080160577A1 (en) * 2005-02-04 2008-07-03 Glaxo Group Limited Optimization of Heterologous Polypeptide Expression
KR100655438B1 (ko) * 2005-08-25 2006-12-08 삼성전자주식회사 자기 기억 소자 및 그 형성 방법
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
PL2086642T3 (pl) * 2006-10-18 2015-02-27 Periness Ltd DNaza do leczenia męskiej subpłodności
PL2840090T3 (pl) 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
WO2009123950A2 (en) * 2008-03-31 2009-10-08 The Trustees Of The University Of Pennsylvania Chimera comprising bacterial cytotoxin and methods of using the same
GB2474225A (en) * 2009-07-21 2011-04-13 Biotec Pharmacon Asa DNase for decontamination of reverse transcription and amplification reactions
EP3318634A1 (en) 2011-04-21 2018-05-09 University of Massachusetts Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
MX2016017115A (es) 2014-06-25 2018-01-12 Jhl Biotech Inc Metodos y reactivos para la purificacion de proteinas.
JP6071018B2 (ja) 2014-10-31 2017-02-01 Ｊｃｒファーマ株式会社 組換えヒトＤＮａｓｅＩの製造方法
CA2988471A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
WO2021244964A1 (en) 2020-06-01 2021-12-09 Black Cat Bio Limited Compositions and methods for treating infections and netopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Boen T. Khouw Isolation and purification of deoxyribonuclease
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
DE68929551T2 (de) * 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Also Published As

Publication number Publication date
CZ293105B6 (cs) 2004-02-18
UA46693C2 (uk) 2002-06-17
RU94046424A (ru) 1997-03-10
NO944752D0 (no) 1994-12-08
MD960288A (ro) 1998-01-31
CA2137237A1 (en) 1993-12-23
KR100323357B1 (ko) 2002-02-19
GB2282140A (en) 1995-03-29
EP0644932B1 (en) 2000-08-09
US5783433A (en) 1998-07-21
AU682822B2 (en) 1997-10-23
FI945549A (fi) 1994-11-25
BR9306670A (pt) 1998-12-08
US20030077267A1 (en) 2003-04-24
JP3383307B2 (ja) 2003-03-04
US5279823A (en) 1994-01-18
GB9423695D0 (en) 1995-01-11
WO1993025670A1 (en) 1993-12-23
GR3034718T3 (en) 2001-01-31
IL105724A0 (en) 1993-09-22
SK282957B6 (sk) 2003-01-09
HU219549B (hu) 2001-05-28
HU9403512D0 (en) 1995-02-28
DE69329200T2 (de) 2001-04-26
NZ253559A (en) 1996-11-26
CA2137237C (en) 2004-10-26
HUT70468A (en) 1995-10-30
US6440412B1 (en) 2002-08-27
EP1013284B1 (en) 2010-01-20
BG62335B1 (bg) 1999-08-31
GEP20002300B (en) 2000-11-25
DK0644932T3 (da) 2001-01-02
TJ396B (en) 2004-12-29
AU4398193A (en) 1994-01-04
EP1013284A3 (en) 2000-08-30
PL175873B1 (pl) 1999-02-26
ATE195340T1 (de) 2000-08-15
JPH07507455A (ja) 1995-08-24
BG99234A (bg) 1995-07-28
DE69334317D1 (de) 2010-03-11
EP0644932A1 (en) 1995-03-29
EP1013284A2 (en) 2000-06-28
IL105724A (en) 1997-06-10
PT644932E (pt) 2001-02-28
DE4392749T1 (de) 1995-07-20
KR100302092B1 (ko) 2001-10-22
RU2238320C2 (ru) 2004-10-20
FI945549A0 (fi) 1994-11-25
US6932965B2 (en) 2005-08-23
CZ303294A3 (en) 1995-06-14
SK149594A3 (en) 1996-01-10
DE69329200D1 (de) 2000-09-14
RO117188B1 (ro) 2001-11-30
GB2282140B (en) 1996-04-17
ATE455557T1 (de) 2010-02-15
NO318644B1 (no) 2005-04-25
NO944752L (no) 1994-12-08

Similar Documents

Publication Publication Date Title
ES2150447T3 (es) Formas purificadas de desoxiribonucleasa.
FI862011A (fi) Terapeutiska nukleosider.
DE3877529T2 (de) Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
HUP0100815A2 (hu) Neurológiai és neuropszichiátriai rendellenességek kezelésére szolgáló gyógyszerkészítmények
IL106842A (en) Pharmaceutical compositions comprising il-4r or derivatives thereof for the treatment, prophylaxis and diagnosis of allergic, viral, parasitic and bacterial diseases and fungal infections
DE3884680D1 (de) Äusseres Membranprotein F von Pseudomonas aeruginosa.
DE3875769D1 (de) Therapeutische nukleoside.
DK347289D0 (da) Terapeutiske forbindelser
ATE84543T1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
ATE96150T1 (de) Thioester und dessen verwendung zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von ischaemie und von reperfusionsyndromen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 644932

Country of ref document: ES